Lack of contribution of P-glycoprotein-mediated transport to renal excretion of pilsicainide in humans

Tsuyoshi Shiga, Masayuki Hashiguchi, Takanori Tanaka, Naomi Morozumi, Shin Irie, Mayumi Mochizuki, Nobuhisa Hagiwara, Hiroshi Kasanuki

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Pilsicainide is a cationic antiarrhythmic agent that has the potential of drug-drug interactions because of Pglycoprotein(P-gp)-mediated transport and organic cation transport of the drug in renal tubules, We evaluated the contribution of P-gp-mediated transport to renal clearance of pilsicainide in humans. A pharmacokinetic study conducted in 8 healthy female subjects (aged 29±4 years body weight 49.8±5.2 kg) showed that verapamil (40 mg given three times a day), a potent P.gp inhibitor, did not significantly affect the renal clearance (pilsicainide alone : 224 ± 34 versus pilsicainide + verapamil : 216 ± 42 mL/min) or net renal clearance by tubular secretion (pilsicainide alone : 155 ± 31 versus pilsicainide + verapamil : 148 ± 35 mL/min) of pilsicainide after a single oral dose (50 mg). Using in vitro studies. pilsicainide stimulated little P.gp ATPase activity in human P-gpexpressing cell membranes. In addition, no concentration dependence was observed in the transcellular basolateral to apical transport of pilsicainide, and the P.gp substrates doxorubicin and vinblastine did not competitively inhibit pilsicainide transport in human P-gp-expressing LLC-GA5-COL150 cells. In conclusion, our results suggest that P-gp-mediated transport has minimal or no contribution to renal tubular secretion of pilsicainide in humans.

Original languageEnglish
Pages (from-to)157-164
Number of pages8
JournalJapanese Journal of Clinical Pharmacology and Therapeutics
Volume43
Issue number3
Publication statusPublished - 2012 May

Fingerprint

P-Glycoprotein
Kidney
Verapamil
pilsicainide
Renal Elimination
Vinblastine
Drug Interactions
Human Activities
Pharmaceutical Preparations
Doxorubicin
Adenosine Triphosphatases
Cations
Healthy Volunteers
Pharmacokinetics
Body Weight
Cell Membrane

Keywords

  • P-glycoprotein
  • Pharmacokinetics
  • Pilsicainide
  • Renal excretion
  • Verapamil

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Lack of contribution of P-glycoprotein-mediated transport to renal excretion of pilsicainide in humans. / Shiga, Tsuyoshi; Hashiguchi, Masayuki; Tanaka, Takanori; Morozumi, Naomi; Irie, Shin; Mochizuki, Mayumi; Hagiwara, Nobuhisa; Kasanuki, Hiroshi.

In: Japanese Journal of Clinical Pharmacology and Therapeutics, Vol. 43, No. 3, 05.2012, p. 157-164.

Research output: Contribution to journalArticle

Shiga, T, Hashiguchi, M, Tanaka, T, Morozumi, N, Irie, S, Mochizuki, M, Hagiwara, N & Kasanuki, H 2012, 'Lack of contribution of P-glycoprotein-mediated transport to renal excretion of pilsicainide in humans', Japanese Journal of Clinical Pharmacology and Therapeutics, vol. 43, no. 3, pp. 157-164.
Shiga, Tsuyoshi ; Hashiguchi, Masayuki ; Tanaka, Takanori ; Morozumi, Naomi ; Irie, Shin ; Mochizuki, Mayumi ; Hagiwara, Nobuhisa ; Kasanuki, Hiroshi. / Lack of contribution of P-glycoprotein-mediated transport to renal excretion of pilsicainide in humans. In: Japanese Journal of Clinical Pharmacology and Therapeutics. 2012 ; Vol. 43, No. 3. pp. 157-164.
@article{1e6240f19a59404f88ab54a4fd89ca32,
title = "Lack of contribution of P-glycoprotein-mediated transport to renal excretion of pilsicainide in humans",
abstract = "Pilsicainide is a cationic antiarrhythmic agent that has the potential of drug-drug interactions because of Pglycoprotein(P-gp)-mediated transport and organic cation transport of the drug in renal tubules, We evaluated the contribution of P-gp-mediated transport to renal clearance of pilsicainide in humans. A pharmacokinetic study conducted in 8 healthy female subjects (aged 29±4 years body weight 49.8±5.2 kg) showed that verapamil (40 mg given three times a day), a potent P.gp inhibitor, did not significantly affect the renal clearance (pilsicainide alone : 224 ± 34 versus pilsicainide + verapamil : 216 ± 42 mL/min) or net renal clearance by tubular secretion (pilsicainide alone : 155 ± 31 versus pilsicainide + verapamil : 148 ± 35 mL/min) of pilsicainide after a single oral dose (50 mg). Using in vitro studies. pilsicainide stimulated little P.gp ATPase activity in human P-gpexpressing cell membranes. In addition, no concentration dependence was observed in the transcellular basolateral to apical transport of pilsicainide, and the P.gp substrates doxorubicin and vinblastine did not competitively inhibit pilsicainide transport in human P-gp-expressing LLC-GA5-COL150 cells. In conclusion, our results suggest that P-gp-mediated transport has minimal or no contribution to renal tubular secretion of pilsicainide in humans.",
keywords = "P-glycoprotein, Pharmacokinetics, Pilsicainide, Renal excretion, Verapamil",
author = "Tsuyoshi Shiga and Masayuki Hashiguchi and Takanori Tanaka and Naomi Morozumi and Shin Irie and Mayumi Mochizuki and Nobuhisa Hagiwara and Hiroshi Kasanuki",
year = "2012",
month = "5",
language = "English",
volume = "43",
pages = "157--164",
journal = "Japanese Journal of Clinical Pharmacology and Therapeutics",
issn = "0388-1601",
publisher = "Japanese Society of Clinical Pharmacology and Therapeutics",
number = "3",

}

TY - JOUR

T1 - Lack of contribution of P-glycoprotein-mediated transport to renal excretion of pilsicainide in humans

AU - Shiga, Tsuyoshi

AU - Hashiguchi, Masayuki

AU - Tanaka, Takanori

AU - Morozumi, Naomi

AU - Irie, Shin

AU - Mochizuki, Mayumi

AU - Hagiwara, Nobuhisa

AU - Kasanuki, Hiroshi

PY - 2012/5

Y1 - 2012/5

N2 - Pilsicainide is a cationic antiarrhythmic agent that has the potential of drug-drug interactions because of Pglycoprotein(P-gp)-mediated transport and organic cation transport of the drug in renal tubules, We evaluated the contribution of P-gp-mediated transport to renal clearance of pilsicainide in humans. A pharmacokinetic study conducted in 8 healthy female subjects (aged 29±4 years body weight 49.8±5.2 kg) showed that verapamil (40 mg given three times a day), a potent P.gp inhibitor, did not significantly affect the renal clearance (pilsicainide alone : 224 ± 34 versus pilsicainide + verapamil : 216 ± 42 mL/min) or net renal clearance by tubular secretion (pilsicainide alone : 155 ± 31 versus pilsicainide + verapamil : 148 ± 35 mL/min) of pilsicainide after a single oral dose (50 mg). Using in vitro studies. pilsicainide stimulated little P.gp ATPase activity in human P-gpexpressing cell membranes. In addition, no concentration dependence was observed in the transcellular basolateral to apical transport of pilsicainide, and the P.gp substrates doxorubicin and vinblastine did not competitively inhibit pilsicainide transport in human P-gp-expressing LLC-GA5-COL150 cells. In conclusion, our results suggest that P-gp-mediated transport has minimal or no contribution to renal tubular secretion of pilsicainide in humans.

AB - Pilsicainide is a cationic antiarrhythmic agent that has the potential of drug-drug interactions because of Pglycoprotein(P-gp)-mediated transport and organic cation transport of the drug in renal tubules, We evaluated the contribution of P-gp-mediated transport to renal clearance of pilsicainide in humans. A pharmacokinetic study conducted in 8 healthy female subjects (aged 29±4 years body weight 49.8±5.2 kg) showed that verapamil (40 mg given three times a day), a potent P.gp inhibitor, did not significantly affect the renal clearance (pilsicainide alone : 224 ± 34 versus pilsicainide + verapamil : 216 ± 42 mL/min) or net renal clearance by tubular secretion (pilsicainide alone : 155 ± 31 versus pilsicainide + verapamil : 148 ± 35 mL/min) of pilsicainide after a single oral dose (50 mg). Using in vitro studies. pilsicainide stimulated little P.gp ATPase activity in human P-gpexpressing cell membranes. In addition, no concentration dependence was observed in the transcellular basolateral to apical transport of pilsicainide, and the P.gp substrates doxorubicin and vinblastine did not competitively inhibit pilsicainide transport in human P-gp-expressing LLC-GA5-COL150 cells. In conclusion, our results suggest that P-gp-mediated transport has minimal or no contribution to renal tubular secretion of pilsicainide in humans.

KW - P-glycoprotein

KW - Pharmacokinetics

KW - Pilsicainide

KW - Renal excretion

KW - Verapamil

UR - http://www.scopus.com/inward/record.url?scp=84862540727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862540727&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84862540727

VL - 43

SP - 157

EP - 164

JO - Japanese Journal of Clinical Pharmacology and Therapeutics

JF - Japanese Journal of Clinical Pharmacology and Therapeutics

SN - 0388-1601

IS - 3

ER -